Search results
Apr 23, 2020 · Just this week, a panel of experts convened by the National Institute of Allergy and Infectious Diseases recommended against doctors using a combination of hydroxychloroquine and the antibiotic azithromycin for the treatment of COVID-19 patients because of potential toxicities.
- Overview
- Laboratory study
- Antiviral effects
- How might it work?
- Clinical trials
•An antimalarial is the latest drug that researchers have identified as a potential COVID-19 treatment.
•In a laboratory study, scientists found that atovaquone inhibited replication of SARS-CoV-2 in human lung cells.
•The effects occurred in vitro against Alpha, Beta, and Delta variants.
•Clinical trials are necessary to see whether it is possible to repeat these results in people with COVID-19.
All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub for the most recent information on COVID-19.
Was this helpful?
Now, a Danish laboratory study has published results suggesting that atovaquone has a protective effect against coronavirus in human lung cells. Atovaquone is part of the antimalarial Malarone, which doctors have used for the treatment and prevention of malaria since 1999.
Speaking to Medical News Today, Dr. William Schaffner, a professor of infectious diseases at the Vanderbilt University Medical Center, Nashville, TN, welcomed the study: “Everybody’s excited when a drug that’s been in use before [looks promising in the laboratory] because obviously, we have a great deal of clinical experience to back it up. It’s already licensed. But now we have to see if it really does work in people. That’s a giant step.”
The study by a team at Aarhus University found that atovaquone blocked infection from Alpha, Beta, and Delta variants of COVID-19 in human lung cells in vitro.
However, Dr. Schaffner urged caution: “Of course, it’s a laboratory study. Which means it is provocative but early. I hate to put it in the same category, but [I] was just thinking of another study that looked good in the lab but fizzled — the hydroxychloroquine study.”
Researchers instigated the study following anecdotal evidence from Canada that people taking Malarone appeared to have some resistance to COVID-19. Either they were not contracting the virus, or the symptoms were not severe if they did.
Researchers have investigated the antiviral potential of atovaquone previously. A 2019 study showed that it inhibited the reproduction of the Zika virus in vitro. In this study, researchers suggested that atovaquone was inhibiting RNA replication, thus preventing the virus from reproducing.
The researchers posited several possible mechanisms for atovaquone’s observed effect on SARS-CoV-2. They suggest that it may inhibit viral replication, prevent binding of the spike protein to the ACE2 receptors, and prevent the expression of inflammatory markers.
“I don’t want to criticize the study, but I’m not convinced it’s an enormous step forward. I’d like to be proved wrong. I’d like the clinical data to come up that it really does something.” Dr. Jonathan Stoye, a virologist at the Francis Crick Institute in London, United Kingdom, told MNT.
Two small clinical trials of atovaquone are already underway. One, a stage 2 trial in Texas, finished in January this year, but the results were not publicized. This raises questions for Dr. Stoye: “I would like to see some data from this clinical trial. I just wonder what it actually showed. You would have thought that if it showed something, we would have heard of it.”
Whether researchers are planning larger clinical trials is unknown. As Dr. Schaffner commented: “Leaping to a clinical trial is a very, very large investment. You have to be very convinced that something is going to work.”
“I have reservations about the importance of this study. That’s my bottom line.”
– Dr. Jonathan Stoye
Atovaquone may have potential, but more evidence is needed. The hunt for effective COVID-19 treatments continues.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.
Aug 25, 2023 · Hydroxychloroquine, an FDA-approved prescription drug used for malaria, rheumatoid arthritis and lupus erythematosus, has been suggested as a possible treatment or preventive for COVID-19 based on demonstrated antiviral or immune system activity.
Jul 30, 2020 · For detection and treatment of malaria, individuals may stop attending health facilities, out of fear of exposure to COVID-19, or because they cannot afford transport, and health care workers require additional resources to protect themselves from COVID-19.
- Stephen J. Rogerson, James G. Beeson, Moses Laman, Jeanne Rini Poespoprodjo, Timothy William, Julie ...
- 2020
Sep 6, 2020 · Another method for diagnosing malaria is to search for parasite nucleic acids using polymerase chain reaction (PCR). Although this technique may be much more sensitive than smear microscopy, PCR results are often not available quickly enough and are therefore rarely used.
- Francesco Di Gennaro, Claudia Marotta, Pietro Locantore, Damiano Pizzol, Giovanni Putoto
- 2020
Aug 23, 2022 · Understanding the dynamics of COVID-19 infection in Sub-Saharan Africa and how it is shaped by another endemic disease like malaria can provide insights into how to tailor a successful diagnostic, intervention, and control plans that lower both disease morbidity and mortality.
Jul 13, 2021 · This relationship with the Serum Institute, forged to produce malaria vaccines, was instrumental in facilitating a pandemic collaboration to produce another vaccine developed in part by Hill and...
